Nature medicine
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.
Renee R Fedak, Rachel N Ruggerie, Yufei Shan, Elizabeth J Curvino, Juliana F de Sousa, Shaji Daniel, Minhtran Ngo-Casi, Hafsa Kamboh, Tuan Vu, Hacer Durmuş, Tahseen Mozaffar, James F Howard, Emily P English, Albina Benson, Matthew T Duvernay
Published: 202610.1038/s41591-025-04170-z
Abstract
Chimeric antigen receptor (CAR)-T cell therapies have the potential to transform treatment of autoimmune disease by resetting the immune system. However, adoption of cell therapies in the autoimmune space is limited by hurdles such as inpatient admin…
Preview only. Read the full abstract at the source